0.00Open0.05Pre Close0 Volume108 Open Interest22.50Strike Price0.00Turnover433.50%IV152.80%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0360Delta0.0194Gamma178.40Leverage Ratio-0.0318Theta0.0000Rho6.43Eff Leverage0.0007Vega
Emergent BioSolutions Stock Discussion
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
Just
Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted
Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
$Synopsys (SNPS.US)$ $Futu Holdings Ltd (FUTU.US)$ $IonQ Inc (IONQ.US)$
No comment yet